Background Immunotherapy has wholly changed how cancer is treated by using the body’s immune system to eliminate cancer cells. Cancer vaccines, chimeric antigen receptor T-cell (CAR-T) treatments, and immune checkpoint inhibitors (ICIs) are at the forefront, each with a unique method for boosting anti-tumor immunity. Despite its success, there are still issues with resistance mechanisms, limited effectiveness in some types of cancer, and optimizing combination treatments. Purpose The goal of this study is to give a comprehensive summary of the pharmacological approaches to cancer immunotherapy, such as cancer vaccines, CAR-T cell treatments, and ICIs. It overviews these treatments’ mechanics, clinical activity, ongoing clinical studies, difficulties, and potential prospects. Materials and Methods A thorough search of the available literature and clinical trial data was used to perform the narrative review. The study incorporated publications from several sources, including PubMed and clinical trial registries, to provide a current picture of the state of cancer immunotherapy. Critical therapeutic approaches were examined in light of new therapy paradigms, clinical findings, and molecular causes. Results ICIs, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, have shown promise, particularly in treating non-small-cell lung cancer (NSCLC) and melanoma. Trials are being conducted to assess the use of CAR-T cell therapy in solid tumors after it demonstrated efficacy in hematologic malignancies. The future is being transformed by cancer vaccinations, both preventative (like the human papillomavirus (HPV) vaccine) and therapeutic, with combination therapy showing promise in overcoming resistance and enhancing effectiveness. Conclusion ICIs, CAR-T cells, and cancer vaccines are driving the revolution in cancer immunotherapy. Even though the treatments offer much promise, additional research is needed to overcome the limitations of the present day, increase response rates, and expand their uses. Clinical trials and innovation will determine the future of cancer treatment.
Yadav et al. (Mon,) studied this question.